Completed PHASE3 INTERVENTIONAL 2-arm NCT06068465

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease

Sponsor: Tasly Pharmaceutical Group Co., Ltd

Conditions Parkinson's Disease Psychosis

Interventions pimavanserin tartrate placebo

Updated 7 times since 2023 Last updated: Feb 25, 2026 Started: Sep 27, 2024 Primary completion: Feb 1, 2026 Completion: Feb 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06068465, this PHASE3 trial focuses on Parkinson's Disease Psychosis and remains completed. Sponsored by Tasly Pharmaceutical Group Co., Ltd, it has been updated 7 times since 2024, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

7 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE3

Status: Recruiting → Completed
Sep 2025 — Feb 2026 [monthly]

Recruiting PHASE3
Feb 2025 — Sep 2025 [monthly]

Recruiting PHASE3
Oct 2024 — Feb 2025 [monthly]

Recruiting PHASE3
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE3

▶ Show 2 earlier versions

Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Jul 2024 [monthly]

Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tasly Pharmaceutical Group Co., Ltd

Data source: Tasly Pharmaceutical Group Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Fuzhou, China , Guangzhou, China , Guiyang, China , Hefei, China , Hohhot, China and 14 more locations